Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

Ejemplares similares

• Influence of severity of illness on the effects of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis
  por: Opal, SM, et al.
  Publicado: (2009)
• Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
  por: Nagy, CF, et al.
  Publicado: (2011)
• Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males
  por: Okubo, Y, et al.
  Publicado: (2011)
• Respiratory Syncytial Virus Fusion Protein-Induced Toll-Like Receptor 4 (TLR4) Signaling Is Inhibited by the TLR4 Antagonists Rhodobacter sphaeroides Lipopolysaccharide and Eritoran (E5564) and Requires Direct Interaction with MD-2
  por: Rallabhandi, Prasad, et al.
  Publicado: (2012)
• Eritoran: the evidence of its therapeutic potential in sepsis
  por: Raja, Shahzad G., et al.
  Publicado: (2007)